Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC

Radiotherapy and Oncology

Volumn 91, Issue 3, 2009, Pages 438-442

  Bral, Samuel ^a   Duchateau, Michaël ^a   De Ridder, Mark ^a   Everaert, Hendrik ^a   Tournel, Koen ^a   Schallier, Denis ^a   Verellen, Dirk ^a   Storme, Guy ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Chemoradiation; Local response; Lung cancer; Megavoltage computed tomography (MVCT)

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; ESOPHAGUS DISEASE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MEGAVOLTAGE COMPUTER ASSISTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 65649142623     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.03.015     Document Type: Article

References (34)

1. Auperin A., Le Pechoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 3 (2006) 473-483
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 9 (1999) 2692-2699
3. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 25 (2005) 5910-5917
4. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 1 (2004) 87-98
5. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 5 (2000) 1475-1482
6. Werner-Wasik M., Swann R.S., Bradley J., et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2 (2008) 385-390
7. Arpin D., Perol D., Blay J.Y., et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 34 (2005) 8748-8756
8. Anscher M.S., Marks L.B., Shafman T.D., et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 17 (2001) 3758-3765
9. Kupelian P.A., Ramsey C., Meeks S.L., et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 4 (2005) 1024-1028
10. Seibert R.M., Ramsey C.R., Hines J.W., et al. A model for predicting lung cancer response to therapy. Int J Radiat Oncol Biol Phys 2 (2007) 601-609
11. Woodford C., Yartsev S., Dar A.R., Bauman G., and Van Dyk J. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys 4 (2007) 1316-1322
12. Schallier D., Neyns B., Fontaine C., et al. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Lung Cancer 2 (2007) 247-254
13. Mehta M., Scrimger R., Mackie R., et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1 (2001) 23-33
14. Mackie T.R., Holmes T., Swerdloff S., et al. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 6 (1993) 1709-1719
15. Mackie T.R. History of tomotherapy. Phys Med Biol 13 (2006) R427-R453
16. Ruchala K.J., Olivera G.H., Schloesser E.A., and Mackie T.R. Megavoltage CT on a tomotherapy system. Phys Med Biol 10 (1999) 2597-2621
17. Boswell S., Tome W., Jeraj R., Jaradat H., and Mackie T.R. Automatic registration of megavoltage to kilovoltage CT images in helical tomotherapy: an evaluation of the setup verification process for the special case of a rigid head phantom. Med Phys 11 (2006) 4395-4404
18. Langen K.M., Zhang Y., Andrews R.D., et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 5 (2005) 1517-1524
19. Woodford C., Yartsev S., and Van Dyk J. Optimization of megavoltage CT scan registration settings for thoracic cases on helical tomotherapy. Phys Med Biol 15 (2007) N345-N354
20. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 1 (2005) 95-108
21. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 6 (2006) 1059-1066
22. Decoster L., Schallier D., Everaert H., et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography ((18)FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 62 (2008) 55-61
23. Rowell N.P., and O'rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 4 (2004) [CD002140]
24. Vokes E.E., Herndon J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
25. Van Der Kogel A. Radiation response and tolerance of normal tissue. In: Steel GO, editor. Basic Clinical Radiobiology. 3rd Edition, Arnold. 2002;30-41.
26. Van de S.J., Linthout N., De Mey J., et al. Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol 1 (2002) 37-49
27. Siker M.L., Tome W.A., and Mehta M.P. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect. Int J Radiat Oncol Biol Phys 1 (2006) 135-141
28. Welsh J.S., Bradley K., Ruchala K.J., et al. Megavoltage computed tomography imaging: a potential tool to guide and improve the delivery of thoracic radiation therapy. Clin Lung Cancer 5 (2004) 303-306
29. Fox J., Ford E., Redmond K., et al. Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 10.1016/j.ijrobp.2008.07.063
30. Kong F.M., Frey K.A., Quint L.E., et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 21 (2007) 3116-3123
31. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 7 (2003) 1285-1292
32. Lee J.G., Lee C.Y., Park I.K., et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 1 (2008) 211-215
33. Geus-Oei L.F., van der Heijden H.F., Corstens F.H., and Oyen W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 8 (2007) 1654-1664
34. Auperin A., Rolland E., Curran W., Furuse K., Fournel P., Belderbobs J., Clamon G., Ulutin H., Stewart L., and Le Pechoux C. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2 (2007) S310